Halozyme Therapeutics, Inc. vs. Sana Biotechnology, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$107.20 +0.19%
VS SANASana Biotechnology, Inc. Common Stock
$3.13 +1.29%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| HALO | SANA | |
|---|---|---|
| Market Cap | $12.14 billion | $925.02 million |
| Revenue (TTM) | $1.66 billion | — |
| Net Income (TTM) | $413.60 million | $-211,822,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | SANA | |
|---|---|---|
| P/E Ratio | 31.25 | — |
| Price / Book | 84.60 | 5.98 |
| Price / Sales | 7.30 | — |
SANA leads on 1 of 1 valuation factors.
Profitability
| HALO | SANA | |
|---|---|---|
| Net Margin | 24.86% | — |
| Return on Equity | 288.13% | -137.04% |
HALO leads on 1 of 1 profitability factors.
Risk & Sentiment
| HALO | SANA | |
|---|---|---|
| Short Interest | 9.79% | 0.18% |
SANA leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, SANA overview, SANA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.